GT Biopharma (GTBP)
NASDAQ:GTBP
Holding GTBP?
Track your performance easily

GT Biopharma (GTBP) Financial Statements

216 Followers

GT Biopharma Financial Overview

GT Biopharma's market cap is currently ―. The company's EPS TTM is $-7.72; its P/E ratio is -0.28; GT Biopharma is scheduled to report earnings on October 29, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Jun 23Mar 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -3.71M$ 2.27M$ -2.96M$ -1.99M$ 39.00K
EBITDA$ -3.68M$ 2.29M$ -2.96M-$ 64.00K
Net Income Common Stockholders$ -3.71M$ -2.30M$ -2.96M$ -1.99M$ 251.00K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 9.25M$ 9.85M$ 13.98M$ 17.97M$ 19.95M
Total Assets$ 9.27M$ 9.91M$ 14.11M$ 18.14M$ 20.13M
Total Debt$ 0.00$ 30.00K$ 58.00K$ 120.00K$ 147.00K
Net Debt$ -9.25M$ -9.82M$ -13.92M$ -17.85M$ -19.80M
Total Liabilities$ 3.76M$ 4.60M$ 6.63M$ 6.38M$ 7.03M
Stockholders Equity$ 5.50M$ 5.30M$ 7.48M$ 11.76M$ 13.05M
Cash Flow-
Free Cash Flow$ -3.50M$ -4.20M$ -2.05M-$ -2.90M
Operating Cash Flow$ -3.50M$ -4.20M$ -2.05M-$ -2.90M
Investing Cash Flow$ 7.86M$ 5.03M$ 478.00K-$ -6.99M
Financing Cash Flow$ 2.98M---$ 6.27M
Currency in USD

GT Biopharma Earnings and Revenue History

GT Biopharma Debt to Assets

GT Biopharma Cash Flow

GT Biopharma Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis